Buparlisib (BKM120)
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for Buparlisib (BKM120), covering 2017-10-19 to 2026-04-21. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer [Phase 1, Phase 2]